IP2

IP2 | Immunomodulatory Agent for Tumor Antigen Presentation
CAS Number: 2247640-44-2
Molecular Formula: C₃₂H₂₀Na₄O₁₆P₂
Molecular Weight: 814.40 g/mol
Form: Solid
Color: Not specified
Storage Conditions: Refer to Certificate of Analysis
Shipping: Room temperature within continental US; international conditions may vary

Product Overview
IP2 is a cutting-edge immunomodulatory small molecule that enhances the immune system's ability to recognize cancer cells by increasing the presentation of intron-derived antigens known as Pioneer Translation Products (PTPs). IP2 achieves this without cytotoxic effects on cancer cells, making it a highly promising candidate for immunotherapy and tumor-targeting research.

This compound demonstrates a unique capability to selectively boost antigen visibility while maintaining favorable safety and bioavailability profiles in both in vitro and in vivo systems. IP2 has shown efficacy in preclinical tumor models and displays favorable pharmacokinetic properties, including high systemic availability and well-tolerated dosing in mice.

Applications
Cancer immunotherapy research
Tumor antigen presentation studies
Intron-derived epitope targeting
Non-cytotoxic immunomodulation
Preclinical drug screening and validation

In Vitro Activity
IP2 at 35 micromolar concentration enhances immunomodulatory responses in murine MCA205 fibrosarcoma cells by upregulating intron-derived SL8 antigen presentation.
At 10 micromolar for 72 hours, IP2 exhibits no cytotoxic effects in several cancer cell lines, including MCF-7, A549, HCT116, K562, B16F10, and K562R.
The compound demonstrates selective interaction with G-protein-coupled receptors including ADRB1, HRH2, and OPRD1, and inhibits key enzymes such as COX1, PDE3A, and PDE4D2.
IP2 does not induce immunogenic cell death in human osteosarcoma U2OS cells, suggesting a targeted mode of action without triggering broad cellular stress responses.

In Vivo Studies
In murine models, IP2 administered at 2.5 mg/kg intravenously and 5 mg/kg via intratumoral injection three times per week for two weeks has been shown to significantly reduce tumor growth in C57BL/6 mice, including a 50 percent decrease in MCA205 WT fibrosarcoma volume.
Multiple dose ranges, including 50, 100, 250, and 500 mg/kg, were well tolerated in mice, indicating a wide therapeutic window.
IP2 also demonstrates high bioavailability and a moderate elimination half-life in both mice and beagle dogs.

Pharmacokinetic Summary
In mice, IP2 shows a rapid absorption profile with Tmax around 0.08 hours and high systemic exposure following both intraperitoneal and intravenous administration.
In beagle dogs, intravenous dosing results in low clearance and sustained plasma levels, suggesting strong systemic retention.
This data supports the feasibility of IP2 as a drug candidate with favorable pharmacodynamics.

Pharmacokinetic Parameters (Excerpt)
In mice (i.p., 9.103 mg/kg):
Cmax: 2078 ng/mL
Tmax: 0.0833 h
Half-life: 0.8 h
Clearance: 154 mL/min/kg
Bioavailability: 86 percent

In dogs (i.v., 26.76 mg/kg):
Cmax: 272 micrograms/mL
Half-life: 3.8 h
Clearance: 0.69 mL/min/kg
Mean residence time: 3.8 h

Related Antibodies
PFKFB3 Antibody
DUSP1 Antibody
SHP2 Antibody
PTP1B Antibody
INPP4B Antibody
PPP5C Antibody
Additional phosphatase- and kinase-targeting antibodies available upon request

Immunomodulatory small molecule IP2
Non-cytotoxic cancer immunotherapy compound
Intron-derived antigen enhancer
PTP antigen presentation booster
Selective immunomodulation for tumor research
IP2 preclinical compound with high bioavailability

Ordering and Availability
IP2 is supplied as a high-purity research compound. Each batch is tested for quality assurance. Store under the conditions provided in the Certificate of Analysis to preserve stability.

Available for immediate shipping
Ships at room temperature within the continental United States
Custom quantities and bulk orders available upon request